PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB WITH AND WITHOUT VIBOSTOLIMAB (ANTI-TIGIT) IN PATIENTS WITH PD-L1-POSITIVE METASTATIC NSCLC

被引：0

作者：

Hellmann, Matthew ^{[1
]}

Cho, Byoung ^{[2
]}

Juergens, Rosalyn ^{[3
]}

Cheng, Ying ^{[4
]}

de Castro, Gilberto ^{[5
]}

Erman, Mustafa ^{[6
]}

Bauman, Jessica ^{[7
]}

Takahashi, Toshiaki ^{[8
]}

Schwarzenberger, Paul ^{[9
]}

Zhang, Pingye ^{[9
]}

Pietanza, M. Catherine ^{[9
]}

Yang, James Chih-Hsin ^{[10
,11
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[3] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[4] Jilin Canc Hosp, Changchun, Peoples R China

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkey

[7] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[8] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan

[9] Merck & Co Inc, Kenilworth, NJ USA

[10] Natl Taiwan Univ Hosp, Taipei, Taiwan

[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

来源：

关键词：

D O I：

10.1136/jitc-2021-SITC2021.459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

459

引用

页码：A488 / A488

页数：1